AKKARAJU SRINIVAS purchased $12.0M of SRRK (indirect holdings)

AKKARAJU SRINIVAS purchased 289,470 indirectly-held shares of Scholar Rock Holding Corp (SRRK) at an average of $41.45 ($41.31–$41.82, $12.00M total) across 6 trades over 2026-10-23 to 2026-10-26.

Original reporting
SEC EDGAR · AKKARAJU SRINIVAS
Published Oct 27, 2026, 11:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Bullish
high confidence
Mentioned
$SRRK
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKBullishMed
01

Why it matters

The $12M purchase by a director is a fresh, primary disclosure that can influence short‑term price dynamics.

02

Market read

Direct insider buying provides a modest bullish catalyst for SRRK, potentially attracting short‑term traders.

03

What to watch

The purchase was made at a range of $41.31‑$41.82; if the stock is near resistance, the impact may be muted.

Relevance 8/10Novelty 7/10Timing: after-hours filing on Oct 27

Background

Form 4 filings disclose insider transactions; director purchases are closely watched for sentiment cues.

Company-level read

Ticker impact

$SRRKBullishHigh confidence
Context

Director Akkaraju Srinivas bought $12M of SRRK shares, increasing his stake to 723,020 shares.

Expected impact

likely upward pressure as the market prices in insider confidence

Evidence & confidence

A $12M purchase by a director is a material insider transaction that often signals positive outlook, prompting short‑term buying interest.

Market effects

May reinforce positive sentiment for biotech and life‑science service firms.

Limited to US markets where SRRK trades.

Low

Counterpoint

Insider buying could be a routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Scholar Rock Holding Corp

    US‑listed biotech services firm (ticker SRRK).

  • Akkaraju Srinivas

    Director of Scholar Rock who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.